Progressive Increase Of Thymoglobulin Severe Infusion Reactions Used In The Conditioning Regimen Of Allogeneic Stem Cell Transplantation. Comparative Study Between 2004 and 2012

Introduction Thymoglobulin (ATG) infusion-related reactions in stem cell transplant (SCT) recipients are frequent. Minor reactions as fever and chills are the most usually observed. Severe and potentially life-threatening reactions are rare (>1/10.000 and Objective To analyze the adverse events observed during ATG infusion in patients undergoing SCT and treated with ATG for GVHD prophylaxis. The emergence of fever, chills, rash, pruritus, gastrointestinal symptoms, cephalea, peripheral edema, hypotension, oligoanuria, pulmonary edema, dyspnea, chest pain, arrhythmia and death during ATG infusion were collected. Premedication with corticosteroids, acetaminophen and antihistaminics, and the needs of additional treatment, oxygen support, diuretics and treatment discontinuations or switch were also analyzed. Patients and Results Sixty-five patients received ATG since 2004 to June 2012. Patients were grouped into three periods: first (2004-2006, 13 patients), second (2007-2009, 25 patients) and third (2010-2012, 27 patients). In all periods total median dose of ATG was 7.5 mg/kg. Fourty-nine patients (75%) developed infusion-associated reaction, being higher into the third period (46%, 72%, 93%, p Conclusion Since 2010, the incidence of moderate and severe ATG infusion-associated reactions in patients undergoing SCT is significantly more frequent than previously and in our opinion these facts may be confirmed in other studies. Disclosures: No relevant conflicts of interest to declare.